Everolimus in the treatment of hormone receptor-positive breast cancer

被引:8
|
作者
Chavez-MacGregor, Mariana [1 ]
Gonzalez-Angulo, Ana Maria [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
关键词
endocrine resistance; everolimus; metastatic breast cancer; mTOR-inhibitors; RANDOMIZED PHASE-II; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; SIGNALING NETWORK; RAPAMYCIN PATHWAY; MAMMALIAN TARGET; HIGH-FREQUENCY; PIK3CA GENE; MTOR; AKT;
D O I
10.1517/13543784.2012.726218
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: The phosphoinositide triphosphate kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) is a central regulatory pathway involved in cell proliferation, growth, differentiation, metabolism and survival. Deregulation of this pathway is well described in breast cancer and is associated to the development of endocrine resistance among hormone receptor (HR)-positive tumors. Everolimus, an mTOR-inhibitor has clinical activity against breast cancer and has shown to restore sensitivity to endocrine therapy. Areas covered: We review the clinical data and the results of the recently published clinical trials evaluating the use of everolimus in HR-positive breast cancer patients in combination with endocrine therapy. We discuss the data regarding efficacy but also describe in detail the side effect profile of this drug. Expert opinion: Everolimus represents a new therapeutic alternative for the treatment of HR-positive metastatic breast cancer. Everolimus is in general a well-tolerated drug, however, stomatitis, fatigue and hematological abnormalities are common. It is still unclear if there are specific subgroups of patients that receive greater benefit from everolimus and whether there is a relationship between the presence of PIK3CA mutations and efficacy. The results of biomarker studies will hopefully provide information that will help us determine which patients are most likely to benefit from this treatment.
引用
收藏
页码:1835 / 1843
页数:9
相关论文
共 50 条
  • [1] EVEROLIMUS TREATMENT FOR HORMONE RECEPTOR-POSITIVE BREAST CANCER
    不详
    [J]. CANCER DISCOVERY, 2012, 2 (01) : 12 - 12
  • [2] Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
    Yi, Zongbi
    Ma, Fei
    [J]. JOURNAL OF BREAST CANCER, 2017, 20 (04) : 321 - 326
  • [3] Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment
    Dobovisek, Luka
    Krstanovic, Fran
    Borstnar, Simona
    Debeljak, Natasa
    [J]. CANCERS, 2020, 12 (03)
  • [4] Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment
    Dhakal, Ajay
    Matthews, Christina M.
    Levine, Ellis Glenn
    Salerno, Kilian Elizabeth
    Zhang, Fan
    Takabe, Kazuaki
    Early, Amy P.
    Edge, Stephen B.
    O'Connor, Tracy
    Khoury, Thaer
    Young, Jessica S.
    Opyrcha, Mateusz
    [J]. CLINICAL BREAST CANCER, 2018, 18 (06) : E1401 - E1405
  • [5] Androgen Receptor in Hormone Receptor-Positive Breast Cancer
    Khan, Ashfia Fatima
    Karami, Samaneh
    Peidl, Anthony S.
    Waiters, Kacie D.
    Babajide, Mariam Funmi
    Bawa-Khalfe, Tasneem
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (01)
  • [6] Everolimus in hormone receptor-positive advanced breast cancer: Targeting receptor-based mechanisms of resistance
    Shtivelband, Mikhail I.
    [J]. BREAST, 2013, 22 (04): : 405 - 410
  • [7] Disparities in Hormone Receptor-Positive Breast Cancer
    Ogayo, Esther R.
    Mittendorf, Elizabeth A.
    Kantor, Olga
    [J]. CURRENT BREAST CANCER REPORTS, 2024, 16 (01) : 106 - 115
  • [8] Palbociclib for hormone receptor-positive breast cancer
    Harding, Emilia
    [J]. LANCET ONCOLOGY, 2015, 16 (07): : E318 - E318
  • [9] Disparities in Hormone Receptor-Positive Breast Cancer
    Esther R. Ogayo
    Elizabeth A. Mittendorf
    Olga Kantor
    [J]. Current Breast Cancer Reports, 2024, 16 : 106 - 115
  • [10] RETRACTION: Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer
    Porta, Camillo
    [J]. ONCOLOGY REVIEWS, 2014, 8 (01) : 6 - 6